Clemens K

Right Solutions Mental Health, LLC, Gaithersburg, MD, USA.

5 papers

ArticleKetamine

Profiles of Medicaid Beneficiaries with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray.

Clemens K, Zhdanava M, Teeple A +6

Europe PMC2025
ArticleKetamine

Assessment of patient-reported depression severity in subpopulation of ESCAPE-TRD study: esketamine nasal spray versus quetiapine extended release for treatment-resistant depression.

Clemens K, Rive B, Joshi K +7

Europe PMC2025
ArticleKetamine

Cost-per-remitter for esketamine nasal spray versus quetiapine for treatment-resistant depression.

Clemens K, Teeple A, Rive B +7

Europe PMC2025
ArticleKetamine

Esketamine Nasal Spray vs Quetiapine Extended-Release: Examining Work Productivity Loss and Related Costs in Patients With Treatment-Resistant Depression.

Clemens K, Teeple A, Zhdanava M +6

Europe PMC2025
ArticleKetamine

Impact of social determinants of health on esketamine nasal spray initiation among patients with treatment-resistant depression in the United States.

Clemens K, Zhdanava M, Teeple A +5

Europe PMC2025